Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...
Novo Nordisk's discounted valuations and promising oral candidate may trigger a drastic reversal in its stock ...
The importance of minority-interest remeasurement has expanded as joint venture and platform-licensing models become more common in biotech. For investors, such metrics provide an improved lens for ...
The leading Familial Chylomicronemia Syndrome Companies such as Ionis Pharmaceuticals, Pfizer, Arrowhead Pharmaceuticals, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback